Serum Institute of India

Codagenix Announces Late-Breaking Presentation of Positive Clinical Immunogenicity Data For COVID-19 Vaccine Candidate CoviLiv™ at IDWeek 2023

Retrieved on: 
Wednesday, October 11, 2023
Vaccine, Serum Institute of India, COVID-19, Viral, Development, Office of Inspector General, U.S. Department of Health and Human Services, Trial of the century, Solidarity trial, Immunity, Therapy, Project, Safety, Oncology, Administration, World Health Organization's response to the COVID-19 pandemic, WHO, Vaccination, Biomedical Advanced Research and Development Authority, Immunology, Messenger, BARDA, Administration for Strategic Preparedness and Response, HHS, Patient, Pharmaceutical industry

FARMINGDALE, N.Y., Oct. 11, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced the late-breaking presentation of positive clinical data for its CoviLiv™ COVID-19 vaccine candidate at the upcoming IDWeek 2023 annual meeting, taking place in Boston on October 11-15, 2023.

Key Points: 
  • Data show that participants who received two doses of 5x106 PFU of CoviLiv showed robust induction of both humoral and cellular immune responses.
  • T cell reactivity was demonstrated to be specific for multiple viral antigens beyond the frequently mutating spike protein.
  • The vaccine was designed using the Codagenix platform technology that re-codes the genetic material of a virus – converting the virus from a disease-causing pathogen into a stable and safe, live-attenuated vaccine.
  • SIIPL, the world's largest vaccine manufacturer by number of doses produced and sold globally, is manufacturing the vaccine for this clinical study.

'We could eradicate malaria by 2040' says expert after revolutionary vaccine is approved by WHO

Retrieved on: 
Tuesday, October 3, 2023
People, Well, Vaccine, Infection, University of Oxford, Serum Institute of India, International, Human, University, Parasitism, Vaccination, COVID-19, Jenner Institute, Immunity, Smallpox, Antibody, Blood, Biological life cycle, Coma, World Health Organization, Liver, World, Gene, Skin, Pharmaceutical industry, Oyster farming, UNICEF, Malaria

Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces malaria by up to 75%.

Key Points: 
  • Trials have shown that the R21/Matrix vaccine, developed by Oxford University together with the Serum Institute of India, reduces malaria by up to 75%.
  • The Conversation Weekly spoke to chief investigator Adrian Hill, who is also director of the Jenner Institute at the University of Oxford, about this revolutionary vaccine.

Why is the R21/Matrix vaccine a game-changer?

    • The best vaccine prior to this was about 50% over a year, and lower than that over three years.
    • The big difference is how you can manufacture it at a scale that is really needed to protect most of the children who need a malaria vaccine in Africa.
    • There are about 40 million children born every year in malaria areas in Africa who would benefit from a vaccine.

Why has developing a malaria vaccine been so difficult?

    • Malaria is not a virus, it’s not a bacterium.
    • This is one of the reasons that malaria is super complex.
    • If you can get a really good vaccine for one of those, you will break the cycle of transmission.
    • It’s a silent infection until it gets into the blood and starts multiplying inside your red blood cells.
    • So the sporozoite is a natural target to try and kill the parasite before it multiplies very quickly.

Tell us about past attempts to develop a malaria vaccine

    • In about 1943, there was a trial of the whole malaria parasite vaccine candidate in New York with zero efficacy.
    • And then within 10 years we had 5,000 candidates because everyone hoped that the gene they had sequenced might be a malaria vaccine.

Why aren’t vaccines for whole parasites effective against malaria?

    • It’s the same reason that just getting infected once by malaria doesn’t give you protection against the next infection.
    • In the areas of malaria where we test our vaccines in Africa, some children get up to eight episodes in three or four months.
    • They get quite unwell with the first and three weeks later they’re having a second bout and so on.

Will we ever eradicate malaria entirely?

    • Malaria is very high on the list of diseases we want to eradicate.
    • I don’t think it’s going to happen in five years or 10 years, but it should happen in something like 15 years.

The long road to a new malaria vaccine, told by the scientists behind the breakthrough – podcast

Retrieved on: 
Tuesday, October 3, 2023
National Institute of Malaria Research, GSK, Music, National Emergency Training Center, University, RSS, R21, Malaria, World Health Organization, Jenner Institute, Serum Institute of India, Child, Blood, Institute, Parasitism, Liver, WHO, World, Research, Lancet, III, Imperial College London, RTS, University of Bamako, Vaccine, Pharmaceutical industry

In this episode of The Conversation Weekly podcast, we find out why it’s been so hard to find a malaria vaccine – and hear from the scientists behind the new breakthrough.

Key Points: 
  • In this episode of The Conversation Weekly podcast, we find out why it’s been so hard to find a malaria vaccine – and hear from the scientists behind the new breakthrough.
  • In 2021, 619,000 people died from malaria, the majority of them children.
  • The search for a vaccine has been underway for decades, but it’s particularly difficult due to the complexity of the malaria parasite.
  • “It begins with a mosquito bite,” says Faith Osier, co-director of the Institute of Infection at Imperial College London.

AHF Slams J&J’s Vaccine Hostage Tactics in South Africa

Retrieved on: 
Thursday, September 7, 2023
COVID-19, Infectious Diseases, Advocacy Group Opinion, Public Policy, Government, Healthcare Reform, AIDS, Health, Pharmaceutical, General Health, Vaccine, Global North and Global South, AHF, Health policy, HIV, Associated Press, Multimedia, Hoarding, J&J, Bullying, NGO, COVID-19 vaccine, AIDS Healthcare Foundation, Serum Institute of India, European, VOW, Johnson & Johnson, Pfizer, Pharmaceutical industry, EU, Policy

According to a Health Policy Watch story , Johnson & Johnson (J&J) used scarcity during the COVID-19 pandemic as leverage to charge South Africa inflated prices on vaccine doses – a tactic that the AIDS Healthcare Foundation (AHF) has decried as ruthless pharma profiteering.

Key Points: 
  • According to a Health Policy Watch story , Johnson & Johnson (J&J) used scarcity during the COVID-19 pandemic as leverage to charge South Africa inflated prices on vaccine doses – a tactic that the AIDS Healthcare Foundation (AHF) has decried as ruthless pharma profiteering.
  • Advocates charged J&J with refusing to expand global production of its vaccine by withholding patents and manufacturing know-how from other producers and for exporting vaccines produced in South Africa to Europe while 94% of people in Africa remain unvaccinated due to severe vaccine shortages.
  • On the continent with virtually no vaccines at the time and aggressive vaccine hoarding by the Global North, South Africa had no choice but to agree to whatever J&J demanded.
  • “The situation in South Africa is the clearest indication yet of why we need a strong Global Public Health Convention based on transparency, accountability, and cooperation.

Fina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM197

Retrieved on: 
Thursday, July 27, 2023
CRM197, GSK plc, Partnership, Attenuated vaccine, Business, Escherichia coli, Diphtheria, Scorpius, CDMO, CGMP, Patient, SAN, Serum Institute of India, Vaccine, Tourism

SAN ANTONIO, July 27, 2023 /PRNewswire/ -- Fina Biosolutions has selected Scorpius BioManufacturing , a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM197 conjugate vaccine carrier protein.

Key Points: 
  • SAN ANTONIO, July 27, 2023 /PRNewswire/ -- Fina Biosolutions has selected Scorpius BioManufacturing , a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM197 conjugate vaccine carrier protein.
  • "Fina Biosolutions is an innovative biotech company that deserves the responsiveness traditional CDMOs often fail to provide to smaller, more nimble clients.
  • They are exactly the type of partner we envisioned supporting when we founded Scorpius in 2020," said Jeff Wolf, Scorpius' Founder and Executive Chairman.
  • To learn more about Fina Biosolutions' conjugate vaccine technology and services, visit FinaBio.net .

Global Single-use Bioreactors Market 2023 to 2030: Increasing Adoption of SUBs Among Small Companies and Startups Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 7, 2023
Biotechnology, Health, Other Manufacturing, Manufacturing, Serum Institute of India, Vaccine, Submarine, COVID-19, Growth, ABEC, Investment, Nature, Buffer, USD, Fine chemical

The global single-use bioreactors market size is expected to reach USD 12.06 billion by 2030, registering a CAGR of 17.19% from 2023 to 2030.

Key Points: 
  • The global single-use bioreactors market size is expected to reach USD 12.06 billion by 2030, registering a CAGR of 17.19% from 2023 to 2030.
  • Owing to the rising demand for biopharmaceuticals, coupled with increasing investments in single-use technologies, the market for single-use bioreactors is expected to witness significant growth throughout the forecast period.
  • The segment is being driven by the increasing usage of single-use bioreactors for mammalian cell culture in several research studies.
  • Factors such as rising investments and funding initiatives among Asian companies are expected to drive the market in the region.

EQS-News: VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana

Retrieved on: 
Wednesday, May 10, 2023
Vaccine, University of Oxford, DEK, Partnership, University, All, VPM, SII, Malaria, African, Licensure, Death, Serum Institute of India, Disease, Mortality, FDA, Pharmaceutical industry, Health

This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa.

Key Points: 
  • This synergistic collaboration facilitated the accelerated licensure process in Ghana and is a step forward on the path to ensuring vaccine equity in Africa.
  • Malaria is one of the leading causes of pediatric morbidity and mortality in sub-Saharan Africa.
  • R21/Matrix-MTM has emerged as the most effective vaccine against malaria ever produced and shall contribute to alleviating the burden of 600,000 deaths per year.
  • The licensure of the R21/Matrix-M Malaria Vaccine for use in Ghana and Nigeria is a significant milestone in our efforts to combat malaria around the world.

2023 ISPE Facility of the Year Awards (FOYA) Category Winners Announced

Retrieved on: 
Wednesday, May 10, 2023
Nexus, Social impact, Takeda, Global health, Development, Contract research organization, Patient, Member, Mab, Supply, API, Health, Serum Institute of India, Pharma, ISPE, Safety, Carbon footprint, CSC, COVID-19, Serum, IPS, Chugai Pharmaceutical Co., Honorable Mention, Agility, COVID, Fine chemical, Vaccine, Genentech

NORTH BETHESDA, Md., May 9, 2023 /PRNewswire-PRWeb/ -- ISPE today announced the 2023 Facility of the Year Awards (FOYA) Winners at the 2023 ISPE Europe Annual Conference in Amsterdam, The Netherlands. The award-winning projects selected by the FOYA program set the standard for pharmaceutical facilities of the future by demonstrating excellence in facility design, construction, and operations.

Key Points: 
  • The Innovation Category was awarded to Chugai Pharma Manufacturing Co., Ltd. for its facility in Shizuoka Pref, Japan for the FJ2 Project.
  • Chugai implemented several innovative design and equipment concepts in the facility to protect both the product and the worker.
  • The Operations Category was awarded to WuXi Biologics Ireland Limited for its Contract Research, Development and Manufacturing Organization (CRDMO) facility in County Louth, Ireland.
  • The 2023 FOYA Category Winners will be formally recognized at the ISPE Facility of the Year Awards Banquet and Dinner on 15 October 2023, in Las Vegas, Nevada, where the 2023 FOYA Overall Winner will also be announced.

African vaccines: local manufacturers are struggling to access the market - what must change

Retrieved on: 
Tuesday, April 25, 2023
Vaccine, Hexavalent vaccine, Workforce, GSK, Partnership, Employment, Public, Survival, Goal, Serum Institute of India, Investment, African Union, WHO, World, Morale, African, Technology transfer, Pfizer, Pharmaceutical industry, Public utility, Tourism, Creative industries, Pneumococcal conjugate vaccine, Health, Sanofi

The hub was launched in mid-2021 in a bid to make the latest vaccine technology more readily available to developing countries.

Key Points: 
  • The hub was launched in mid-2021 in a bid to make the latest vaccine technology more readily available to developing countries.
  • The other development highlighted the main problem that African countries continue to have in developing vaccine production capabilities: markets for their products.
  • This is a local company that’s developed the capacity to manufacture the vaccine in South Africa through a technology transfer partnership with Pfizer.
  • The tender outcome is truly paradoxical given that South Africa has expressed a strong commitment to local production of medicines.

Market access and local production

    • The tender decision raises important questions about local production and how its inextricably linked to market access.
    • Since 2021, vaccine production initiatives in Africa have mostly focused on financing and partnership building, leaving out the central question of market access for products made in African countries.
    • Market access is crucial for local production of vaccines.
    • If the aim is to enable local vaccine production in Africa, we have to ensure that local producers have access to their national markets.

Procurement


    Procurement policies can potentially promote three broad goals:
    But balancing these three goals is not easy. Focusing just on the lowest prices may in fact, lead to the elimination of local companies, driving them out of business. This is why countries that have succeeded in building local vaccine manufacturing had done so by, among other things:
    • A reliance on preferential procurement by local companies can sometimes have negative consequences.
    • But these can be avoided by designing procurement policies that support local companies more broadly, with a focus on promoting competition.

What Africa needs

    • This basis needs to be preserved and nurtured, to enable the company to expand, and to allow the emergence of a vibrant vaccine production sector in the country that can supply to South Africa and the region.
    • This would help local companies to stabilise themselves in Africa, which are not equipped to absorb the financial risks of losing out on national tenders.
    • Africa has come a long way, in the post-COVID era, in boosting the morale around local production investment among local and foreign companies.
    • Without this commitment from African governments, the Africa vaccine manufacturing “project” is under serious threat.

GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, March 28, 2023
Partnership, General counsel, Agriculture, PIPE, COVID-19, Green-light, Health, RNA, Lettuce, GRNA, Public expenditure, Plant, EPA, Retirement, Serum Institute of India, Growth, Research, D, Pharmaceutical industry, Renewable energy, Video game

Collaboration Revenue: Collaboration revenue was $2.9 million during the fourth quarter of 2022, compared to none during the fourth quarter of 2021.

Key Points: 
  • Collaboration Revenue: Collaboration revenue was $2.9 million during the fourth quarter of 2022, compared to none during the fourth quarter of 2021.
  • R&D Expenses: Research and development expenses increased by $4.6 million to $32.4 million during the fourth quarter of 2022, compared to $27.8 million during the fourth quarter of 2021.
  • G&A Expenses: General and administrative expenses increased by $2.2 million to $8.6 million during the fourth quarter of 2022, compared to $6.4 million during the fourth quarter of 2021.
  • Net Loss: The Company’s net loss was $38.8 million for the fourth quarter of 2022, compared to $34.7 million during the fourth quarter of 2021
    The Company expects its cash and equivalents of $68.1 million as of December 31, 2022 will be sufficient to fund planned operating expenses and capital expenditures, through the second quarter of 2023.